Login
Illumina NASDAQ: ILMN
Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic analysis.
| Name | Illumina |
| Ticker | ILMN |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Gene Editing - Cell Therapies |
| Price | 300.80 |
| 52W Low/High | 209.20 / 400.74 |
| Market cap | 44 B |
| 1Y Total Return |
-4.70%
Average |
| 1Y Volatility |
46.01%
Less Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic analysis.
Details
| Ticker | ILMN |
| Name | Illumina |
| ISIN | US4523271090 |
| CUSIP | 452327109 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Gene Editing - Cell Therapies |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) |
|
Share as of 11/20/20
| Close Price | 300.80 |
| 52W Low/High | 209.20 / 400.74 |
| Market cap | 44 B |
| 1Y Total Return |
-4.70%
Average |
| 1Y Volatility |
46.01%
Less Risk |
| Beta | 1.28 |
| PE (trailing) |
69.79
High |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | 19.7% |
| Cash from Op. / Cur. Liabilities | 1.00 |
| Diluted Earnings / Share | 4.31 |
| ROE | 14.0% |
| ROIC | 15.7% |
| Price / Revenue | 13.7 |
| Price / Book | 9.5 |
| Price / CF | 39.9 |
| Current Ratio | 3.9 |
| Cur.Liabilities / Tot.Liabilities | 0.4 |
| Financial Leverage | 0.39 |
| in Mils USD |
rolling-year up to September
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
3,238
|
3,458
|
3,242
|
2,593
|
2,371
|
2,141
|
|
| Gross Profit |
2,235
|
2,395
|
2,252
|
1,703
|
1,657
|
1,524
|
|
| R&D |
644
|
662
|
584
|
539
|
489
|
430
|
|
| EBITDA |
1,053
|
1,337
|
1,166
|
1,197
|
750
|
813
|
|
| Operating Income |
715
|
914
|
916
|
519
|
588
|
672
|
|
| Net Income exc. Extra |
638
|
973
|
684
|
782
|
444
|
510
|
|
| per Share | |||||||
| Diluted avg Shares |
148
|
148
|
149
|
148
|
148
|
150
|
|
| EPS exc. Extra |
4.31
|
6.55
|
4.62
|
5.26
|
3.00
|
3.43
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
7,404
|
7,089
|
6,759
|
5,046
|
4,228
|
3,734
|
|
| Cash, Eq & Invt ShortTerm |
3,324
|
3,166
|
3,389
|
2,041
|
1,536
|
1,439
|
|
| Total Current Assets |
4,329
|
4,222
|
4,262
|
2,805
|
2,278
|
2,210
|
|
| Total Non-Current Assets |
3,075
|
2,867
|
2,497
|
2,241
|
1,950
|
1,523
|
|
| Intangibles |
1,046
|
976
|
1,026
|
956
|
1,032
|
1,043
|
|
| Total Liabilities |
2,704
|
2,650
|
3,165
|
2,191
|
1,908
|
1,797
|
|
| Total Current Liabilities |
1,115
|
619
|
1,735
|
665
|
629
|
584
|
|
| Long Term Debt |
1,589
|
2,031
|
1,430
|
1,526
|
1,279
|
1,213
|
|
| Shareholder equity |
4,700
|
4,439
|
3,503
|
2,855
|
2,240
|
1,937
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
1,117
|
908
|
1,136
|
843
|
884
|
560
|
|
| Depreciation |
182
|
193
|
168
|
155
|
136
|
124
|
|
| Cash from Investing |
-624
|
501
|
-1,780
|
-73
|
-112
|
-668
|
|
| Capex |
184
|
217
|
307
|
318
|
224
|
172
|
|
| Cash from Financing |
-550
|
-936
|
639
|
-212
|
-530
|
-165
|
|
| Stock Issued |
-457
|
-299
|
-125
|
-249
|
-261
|
-30
|
|
| Debt (LT) Issued |
0
|
-551
|
730
|
3
|
-95
|
-1,461
|
|
| Free Cash Flow |
1,336
|
-323
|
1,439
|
449
|
347
|
-126
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
19.7%
|
28.1%
|
21.1%
|
29.9%
|
18.8%
|
23.8%
|
|
| NCFO / Op.Income |
156.2%
|
99.3%
|
124.0%
|
162.4%
|
150.3%
|
83.3%
|
|
| Current Ratio |
3.9
|
6.8
|
2.5
|
4.2
|
3.6
|
3.8
|
|
| Financial Leverage D/E |
0.39
|
0.41
|
0.56
|
0.41
|
0.47
|
0.57
|
|
| Return on Capital Avg |
15.7%
|
24.3%
|
21.9%
|
21.8%
|
17.9%
|
21.3%
|
|
| Return on Shareholder Equity |
14.0%
|
24.5%
|
21.5%
|
30.4%
|
21.4%
|
31.8%
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available